More than 11,000 bottles of a widely prescribed blood pressure medication have been recalled nationwide, not because the drug is contaminated, but because the tablets may not dissolve properly once swallowed. For patients with hypertension, that distinction matters greatly: a blood pressure pill that does not dissolve correctly may not control blood pressure at all.
According to the U.S. Food and Drug Administration, more than 11,400 bottles of prescription chlorthalidone pills are affected. On June 5, the drug's manufacturer, India-based Inventia Healthcare Limited, initiated a voluntary recall of certain lots of its 25-mg chlorthalidone tablets. The FDA classified it as a Class II recall on June 22.
The FDA defines a Class II recall as one in which use of or exposure to a product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
Why This Matters
Chlorthalidone is a thiazide-like diuretic prescribed for high blood pressure — a condition affecting approximately 47% of American adults — and for fluid retention (edema). It works by helping the kidneys remove excess sodium and fluid from the body, which reduces blood volume and, in turn, lowers blood pressure. It has been used for decades and is considered one of the more cost-effective first-line treatments for hypertension.
When a blood pressure medication does not work as intended — even if it looks and tastes identical to a working tablet — the patient does not typically feel any different. Uncontrolled hypertension is a silent condition: there are no short-term symptoms to signal that the drug has stopped working. Over time, inadequately controlled blood pressure increases the risk of heart attack, stroke, and kidney damage.
This is why the recall requires physician involvement — and why patients must not stop the medication on their own.
What We Know So Far
The FDA lists the reason for the recall as "failed dissolution specifications." That does not mean the recall involves contamination or a labeling mistake. Instead, it means the tablets failed to meet the required standards tied to how the medication dissolves. If the drug does not dissolve properly, it could lead to incorrect dosages and ineffective or less effective medication.
The specific recall details:
- Drug : Chlorthalidone Tablets, USP, 25 mg
- Manufacturer : Inventia Healthcare Limited, Mumbai, India
- U.S. Distributor : Rising Pharma Holdings, Inc., East Brunswick, New Jersey
- Bottle sizes : 100-tablet bottles (NDC 64980-599-01) and 1,000-tablet bottles (NDC 64980-599-10)
- Batch numbers : RISA24001 (100-count) and RISB24002 (1,000-count)
- Expiration date : April 2027
- Total bottles affected : 11,460
- FDA classification : Class II
Where the Risk Is Highest
Because it is affordable and well-established, chlorthalidone tends to be prescribed broadly, including to older adults and patients who are managing multiple conditions simultaneously. That demographic is also among the most vulnerable when a medication underperforms.
The drug was distributed nationally through Rising Pharma Holdings. Patients who filled chlorthalidone 25 mg prescriptions from pharmacies that source from Rising Pharma with the affected batch numbers are at risk of receiving a product that may not adequately control their blood pressure.
What Doctors and Experts Say
The most important clinical instruction in any blood pressure medication recall is also the one most likely to be misunderstood: do not stop taking the drug without speaking with your physician.
Abrupt discontinuation of antihypertensive medication — even a medication that may be working less effectively than intended — carries its own risks. Rebound hypertension, in which blood pressure spikes after stopping medication suddenly, can trigger cardiac events. Patients who have identified their bottle as potentially affected should contact their prescribing physician or pharmacist before making any changes to their medication regimen.
What the Evidence Shows — and What It Does Not
MedicalDaily Evidence Check
- Drug: Chlorthalidone Tablets USP, 25 mg
- Recall reason: Failed dissolution specifications — tablets may not dissolve at the required rate
- Health consequence: Potentially inadequate blood pressure control; no contamination or toxicity risk
- FDA classification: Class II (temporary or reversible health consequences; remote probability of serious harm)
- What it does not mean: That the drug is toxic; it may simply be less effective than labeled
- What it does not prove: That patients taking affected lots have experienced inadequate control
- What readers should know: Check lot number immediately; contact physician or pharmacist before changing medication
Who Faces the Greatest Risk?
- Adults with hypertension who depend on consistent blood pressure control to prevent cardiac events
- Older adults on fixed regimens where medication failure may not produce obvious symptoms
- Patients taking chlorthalidone as their sole antihypertensive — without a second agent to compensate if the primary drug underperforms
- Patients with heart failure or kidney disease, where blood pressure control is particularly critical
Symptoms and Warning Signs to Watch For
Inadequately controlled hypertension typically produces no symptoms until a complication occurs. However, a hypertensive crisis may produce: severe headache, visual changes or blurred vision, chest pain or shortness of breath, confusion or difficulty speaking, or sudden severe nosebleed.
If you experience any of these symptoms while taking any blood pressure medication, seek emergency medical care immediately.
What You Can Do Now
- Check your bottle immediately. Look for the batch number on the label. The recalled batches are RISA24001 (100-count bottle) and RISB24002 (1,000-count bottle), with an expiration date of April 2027 and NDC numbers 64980-599-01 or 64980-599-10.
- Contact your pharmacist or physician if your bottle matches these details. Your pharmacist can confirm whether your prescription was filled from a recalled lot and can arrange a replacement.
- Do not stop taking your medication without speaking to a healthcare provider first. Even a potentially less-effective pill is preferable to no blood pressure medication while you await replacement.
- Monitor your blood pressure at home if you have a home blood pressure monitor, and report unusual readings to your physician.
- Return the recalled medication to your pharmacy for a replacement. Most retailers have established return and refund policies for recalled products.
Cost and Access: What Patients Should Know
The recalled medication can be returned to the pharmacy where it was purchased. Most pharmacies will replace recalled prescription medication at no additional cost to the patient. For patients without insurance who need a replacement supply of chlorthalidone, GoodRx typically lists generic chlorthalidone 25 mg at under $10 per month at most major pharmacy chains.
What Happens Next
The FDA will update its enforcement database as the recall progresses. MedicalDaily will report if the recall scope is expanded or if additional lot numbers are identified.
The Bottom Line
If you take chlorthalidone 25 mg and your bottle was distributed by Rising Pharma Holdings with batch numbers RISA24001 or RISB24002, contact your pharmacist or physician immediately to confirm whether your supply is affected and arrange a replacement. Do not stop taking your blood pressure medication without medical guidance — the potential risk of uncontrolled hypertension from stopping abruptly can be greater than the risk from taking a tablet that may simply be slightly less effective.
